US 12,151,995 B2
Compounds and compositions for intracellular delivery of therapeutic agents
Kerry E. Benenato, Cambridge, MA (US); Mark Cornebise, Cambridge, MA (US); and Ellalahewage Sathyajith Kumarasinghe, Cambridge, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Sep. 14, 2023, as Appl. No. 18/467,190.
Application 18/467,190 is a continuation of application No. 17/538,217, filed on Nov. 30, 2021.
Application 17/538,217 is a continuation of application No. 16/555,045, filed on Aug. 29, 2019, granted, now 11,220,476, issued on Jan. 11, 2022.
Application 16/555,045 is a continuation of application No. 15/846,084, filed on Dec. 18, 2017, granted, now 10,442,756, issued on Oct. 15, 2019.
Application 15/846,084 is a continuation of application No. 15/476,253, filed on Mar. 31, 2017, granted, now 9,868,691, issued on Jan. 16, 2018.
Application 15/476,253 is a continuation of application No. PCT/US2016/052352, filed on Sep. 16, 2016.
Claims priority of provisional application 62/393,940, filed on Sep. 13, 2016.
Claims priority of provisional application 62/382,740, filed on Sep. 1, 2016.
Claims priority of provisional application 62/333,557, filed on May 9, 2016.
Claims priority of provisional application 62/266,460, filed on Dec. 11, 2015.
Claims priority of provisional application 62/253,433, filed on Nov. 10, 2015.
Claims priority of provisional application 62/252,316, filed on Nov. 6, 2015.
Claims priority of provisional application 62/220,085, filed on Sep. 17, 2015.
Claims priority of provisional application 62/220,091, filed on Sep. 17, 2015.
Prior Publication US 2024/0124388 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 229/12 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/16 (2006.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61K 48/00 (2006.01); C07C 227/16 (2006.01); C07C 227/18 (2006.01); C07C 229/16 (2006.01); C07C 233/36 (2006.01); C07C 233/72 (2006.01); C07C 235/10 (2006.01); C07C 255/24 (2006.01); C07C 263/20 (2006.01); C07C 271/20 (2006.01); C07C 275/14 (2006.01); C07C 279/12 (2006.01); C07C 279/24 (2006.01); C07C 279/28 (2006.01); C07C 279/32 (2006.01); C07C 311/05 (2006.01); C07C 335/08 (2006.01); C07D 207/27 (2006.01); C07D 233/72 (2006.01); C07D 249/04 (2006.01); C07D 263/20 (2006.01); C07D 265/33 (2006.01); C07D 271/06 (2006.01); C07D 271/10 (2006.01); C07D 277/38 (2006.01); C07F 9/09 (2006.01); C07K 14/505 (2006.01)
CPC C07C 229/12 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0073 (2013.01); A61K 9/127 (2013.01); A61K 9/1272 (2013.01); A61K 9/1617 (2013.01); A61K 9/1641 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 31/7105 (2013.01); A61K 38/1725 (2013.01); A61K 38/1816 (2013.01); A61K 47/543 (2017.08); A61K 47/6911 (2017.08); A61K 48/0033 (2013.01); A61K 48/005 (2013.01); C07C 227/16 (2013.01); C07C 227/18 (2013.01); C07C 229/16 (2013.01); C07C 233/36 (2013.01); C07C 233/72 (2013.01); C07C 235/10 (2013.01); C07C 255/24 (2013.01); C07C 263/20 (2013.01); C07C 271/20 (2013.01); C07C 275/14 (2013.01); C07C 279/12 (2013.01); C07C 279/24 (2013.01); C07C 279/28 (2013.01); C07C 279/32 (2013.01); C07C 311/05 (2013.01); C07C 335/08 (2013.01); C07D 207/27 (2013.01); C07D 233/72 (2013.01); C07D 249/04 (2013.01); C07D 263/20 (2013.01); C07D 265/33 (2013.01); C07D 271/06 (2013.01); C07D 271/10 (2013.01); C07D 277/38 (2013.01); C07F 9/091 (2013.01); C07K 14/505 (2013.01); A61K 9/1271 (2013.01); A61K 48/00 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/14 (2017.05); C07C 2601/18 (2017.05)] 30 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or salts or isomers thereof, wherein:
R1 is —R″M′R′ or C5-20 alkenyl;
R2 and R3 are each independently selected from C1-14 alkyl and C2-14 alkenyl;
R4 is —(CH2)nQ, wherein Q is OH and n is selected from 3, 4, and 5;
M and M′ are each independently —C(O)O— or —OC(O)—;
R5, R6, and R7 are each H;
R′ is a linear C1-12 alkyl, or C1-12 alkyl substituted with C6-9 alkyl;
R″ is C3-14 alkyl;
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.